Genitourinary sites

Abstract

Stereotactic body radiotherapy (SBRT) for prostate cancer is rapidly growing in popularity, with multiple large phase II clinical trials showing excellent tumor control and acceptable toxicity. The use of SBRT has also been studied, although less extensively, for other genitourinary sites, including bladder cancer and renal cell carcinoma. We review the literature supporting SBRT for each of these sites and discuss practical aspects of SBRT planning and delivery, including simulation and field design, dose prescriptions and dose constraints, and expected toxicity and management.